each of them dedicated to a specific clinical specialty. These APPs can be associated to pay per use or subscription business models and the first focus of the company will be NASH (Non-Alcoholic Steatohepatitis). The company will offer an assessment of NASH using ultrasound-based tissue parameters to measure fat content in the Liver, Inflammation and fibrosis. The company is leveraging proprietary technologies in Beamforming, Elastography and Signal processing and wishes to expand its research towards AI and e-health specific areas.